Gain-of-function mutations in KRAS and BRAF genes are found in up to 50% of colorectal cancers. These mutations result in the activation of the BRAF/MEK signaling pathway culminating in the stimulation of ERK1/2 mitogen-activated protein kinases. Upon activation, ERK1/2 translocate from the cytoplasm to the nucleus. This process has been shown to be required for the induction of many cellular responses, although the molecular mechanisms regulating ERK nuclear function, especially under oncogenic stimulation, remain to be explored. Herein, we examined the spatiotemporal regulation of ERK1/2 activity upon oncogenic activation of KRAS G12V and BRAF V600E in normal intestinal epithelial crypt cells (IECs). Results demonstrate that expression of these oncogenes markedly stimulated ERK1/2 activities and morphologically transformed IECs. Importantly however, ERK phosphorylation was not observed in the nucleus, but restricted to the cytoplasm of KRAS G12V -and BRAF V600E -transformed IECs. The absence of nuclear ERK phosphorylation was due to a vanadate-sensitive phosphatase activity. Nuclear ERK dephosphorylation was found to be tightly correlated with the rapid expression of DUSP4 phosphatase induced in an MEKdependent manner. In addition, MEK-dependent phosphorylation of T361, T363, S390 and S395 residues highly stabilized DUSP4 protein. Finally, in human colorectal cancer cells, ERK1/2 activities were also confined to the cytoplasm and treatment with pervanadate reactivated ERK1/2 in the nucleus. Accordingly, DUSP4 mRNAs were found to be highly expressed, in an MEK-dependent manner, in all colorectal cancer cells analyzed. These findings indicate that DUSP4 functions as part of a negative feedback mechanism in the control of the duration and magnitude of nuclear ERK activation during intestinal tumorigenesis.
Introduction
KRAS gene is mutated in nearly 35-40% of colorectal tumors at a relatively early stage of the carcinogenic process (Malumbres and Barbacid, 2003) , playing a crucial role in regulating cell proliferation, growth, survival and metastasis formation in colorectal cancer (CRC) (Smakman et al., 2005) . The most studied KRAS effector pathways are the RAF-MEK-ERK mitogenactivated protein kinase and phosphatidylinositol 3-kinase-AKT pathways, with inhibitors of components of both pathways currently under clinical evaluation. Further support for the functional role of these effectors in CRC stems from the identification of mutationally activated BRAF and the p110a catalytic subunit of phosphatidylinositol 3-kinase (pik3ca) Fang and Richardson, 2005; De Roock et al., 2011; Vakiani and Solit, 2011) . Oncogenic mutations of KRAS and BRAF genes found in up to 50-60% of CRCs are mutually exclusive, suggesting that these oncogenes may have similar functions (Rajagopalan et al., 2002; Nagasaka et al., 2004) .
KRAS/BRAF pathway relays its oncogenic signals primarily via the MAP kinase kinases MEK1 and MEK2, which in turn activate ERK1 and ERK2 by phosphorylation of threonine and tyrosine residues within a specific TEY motif. Activated ERK1/2 thereafter phosphorylate various cytoplasmic and membrane targets before translocating to the nucleus to phosphorylate nuclear substrates comprised mainly of transcription factors (Avruch, 2007; Ramos, 2008) . The duration, magnitude and subcellular localization of ERK1/2 activation determine the specificity of cellular response such as cell cycle progression or arrest, cell proliferation or differentiation, cell adhesion or migration and cell survival or death (Ebisuya et al., 2005; Murphy and Blenis, 2006) . One of the first illustrations was demonstrated in neuronal PC12 cells in which transient activation of ERK1/2 by epidermal growth factor was shown to promote cell proliferation, whereas sustained ERK1/2 activation by nerve growth factor led to differentiation (Marshall, 1995) . In intestinal epithelium, ERK1/2 activities are associated with proliferation of undifferentiated crypt cells, whereas differentiation of human enterocytes is correlated with inhibition of ERK signaling (Aliaga et al., 1999) .
Complete activation of ERK1/2 relies on phosphorylation of threonine and tyrosine residues within a specific TEY motif. Termination of the signal is mediated by dephosphorylation of these residues by specific DUalSpecificity Phosphatases (DUSPs) also known as mitogen-activated protein kinase phosphatases (MKP). ERK1/2-targeting DUSPs are divided into two groups depending on their subcellular localization: DUSP1/ MKP-1, DUSP2/PAC-1, DUSP4/MKP-2 and DUSP5 have a nuclear localization, whereas DUSP6/MKP-3, DUSP7/MKP-X and DUSP9/MKP-4 are cytoplasmic owing to a nuclear export signal. All of the ERKtargeting DUSPs contain a docking (D)-domain that enables their binding to ERK1/2 and, in some cases, to other mitogen-activated protein kinase (Jeffrey et al., 2007; Owens and Keyse, 2007) . Nuclear ERK1/2-targeting DUSPs are believed to act as a negative feedback loop as they can be transcriptionally induced in response to ERK1/2 activation (Jeffrey et al., 2007; Kondoh and Nishida, 2007; Owens and Keyse, 2007) .
Although the spatiotemporal regulation of ERK1/2 is a key determinant of biological outcome of ERK signaling, the molecular mechanisms involved are still unexplored, particularly in the context of oncogenic stimulation due to gain-of-function mutations in KRAS or BRAF genes. Hence, this study was undertaken to analyze the spatiotemporal regulation of ERK activity in intestinal epithelial crypt cells (IECs), following expression of colon tumor-associated KRAS and BRAF mutants, namely KRAS G12V and BRAF
V600E
. We show herein that phosphorylated forms of ERK1/2 were absent from the nucleus and restricted to the cytoplasm upon sustained oncogenic stimulation of IECs by KRAS and BRAF, as well as in human CRC cells. Nuclear ERK1/2 dephosphorylation was tightly associated with the rapid induction and post-translational stabilization of the nuclear phosphatase DUSP4.
Results

Expression of KRAS
G12V or BRAF V600E oncogenes morphologically transforms IEC-6 cells Previous reports demonstrated that expression of constitutively active mutants of MEK1 (Komatsu et al., 2005; Voisin et al., 2008; Lemieux et al., 2009) , BRAF (Ikenoue et al., 2004) or KRAS (Nandan et al., 2008) in intestinal epithelial cells (IECs) such as IEC-6 is sufficient to promote their transformation. To examine the spatiotemporal regulation of ERK1/2 activity during oncogenic stimulation of IECs, we engineered two distinct models of IEC-6 cells stably expressing the oncogenic form of human KRAS G12V or an inducible oncogenic form of human BRAF, BRAF
V600E
:ER T1 (Liu et al., 2007) . As expected, KRAS G12V -expressing cells exhibited a persistent stimulation of ERK1/2 (Supplementary Figure S1a ). As reported (Ikenoue et al., 2004) , while parental cells (not shown) and empty vectorexpressing cells exhibited a typical flat epithelial morphology and were contact-inhibited, KRAS G12V cells displayed a morphologically transformed shape (Supplementary Figure S1b ). Pharmacological inhibition of MEK1/2 with U0126 abolished both KRAS G12V -induced ERK1/2 activation and morphological transformation ( Supplementary Figures S1a and b) . In BRAF
:ER cells, treatment with 250 nM 4-hydroxytamoxifen (referred to as Tamoxifen or Tam) persistently activated ERK1/2 as long as Tam was present in the medium (Supplementary Figure 1c) . Similarly to KRAS G12V cells, BRAF V600E -mediated sustained ERK1/2 activation led to rapid morphological transformation in a MEKdependent manner (Supplementary Figure 1d) .
Phosphorylated ERK1/2 is mainly cytoplasmic during oncogenic activation in IECs
Immunofluorescence analysis of subcellular localization of active bi-phosphorylated forms of ERK1/2 in KRAS G12V -expressing cells revealed an increase in ERK phosphorylation but only in the cytoplasm, which was abolished by treatment with U0126 ( Figure 1a , panels 2 and 3). Consistent with these results, activation of ERK1/2 by BRAF V600E :ER for 24 and 48 h resulted in marked increase in ERK1/2 phosphorylation, again mostly in the cytoplasm (Figure 1b , panels 2 and 3). We took advantage of the inducible BRAF
V600E
:ER oncogene to monitor the spatiotemporal localization of phosphorylated ERK during short-term kinetics of stimulation with Tamoxifen. As shown in Figure 1c (panels 1-4), BRAF V600E :ER activation rapidly induced ERK1/2 phosphorylation both in the cytoplasm and nucleus. Thereafter, nuclear phospho-ERK1/2 signal started to dissipate after 90 min (panel 5) to become virtually undetectable after 2 h of stimulation. Concomitantly, cytoplasmic phospho-ERK1/2 signal gradually increased owing to persistent BRAF V600E activation (panels 6-9). Of note, nuclear ERK phosphorylation was never detected, even after 5 days of Tamoxifen treatment (data not shown). Altogether, these results indicate that sustained ERK phosphorylation is restricted to the cytoplasm in IECs expressing oncogenic KRAS and BRAF.
Nuclear ERK1/2 is actively dephosphorylated upon oncogenic BRAF V600E or KRAS G12V stimulation We next verified whether the absence of nuclear phosphorylated ERK was caused by the absence of ERK proteins in the nucleus. In non-stimulated BRAF
:ER cells, the majority of ERK2 was localized in the cytoplasm (Figure 2a, panel 1) . After 14 h of Tamoxifen stimulation, ERK2 signal was localized both in the cytoplasm and the nucleus (Figure 2a , panel 2), whereas phosphorylated ERK1/2 were almost exclusively cytoplasmic (Figure 2a, panel 5) . This suggests that ERK proteins were able to translocate into the ERK-dependent regulation of DUSP4 expression S Cagnol and N Rivard nucleus after Tamoxifen stimulation. We next tested whether the absence of nuclear phospho-ERK1/2 could be due to an increased phospho-ERK1/2 nuclear export through chromosomal region maintenance 1/exportin 1 system (Adachi et al., 1999; Volmat et al., 2001) . As shown in Figure 2a (panels 3 and 6), inhibition of chromosomal region maintenance 1-dependent export with leptomycin B increased the nuclear localization of total ERK2 without increasing nuclear phosphorylated ERK levels. Thus, absence of nuclear phosphorylated ERK1/2 does not result from an increase in nuclearcytoplasmic export of ERK1/2 proteins.
We also verified whether serum stimulation could reactivate nuclear ERK1/2 in cells undergoing oncogenic activation of BRAF. As a positive control, 30 min serum stimulation of quiescent BRAF V600E :ER cells increased nuclear phospho-ERK1/2 signal ( Figure 2b , panel 1). However, in cells previously stimulated with Tamoxifen during 14 h, serum stimulation could not restore nuclear phospho-ERK1/2 ( Figure 2b , panel 2), suggesting that nuclear ERK1/2 were rapidly dephosphorylated by phosphatase activity. We verified this hypothesis by treating the cells with pervanadate, a broad-spectrum inhibitor of tyrosine phosphatases and DUSPs (Huyer et al., 1997) . As shown in Figure 2b (panel 3), 30 min pervanadate treatment was sufficient to enable the detection of phosphorylated ERK1/2 in the nucleus of cells pre-stimulated with Tamoxifen. Similar results were also observed in KRAS G12V cells (Figure 2c ). These data thus indicate that persistent tyrosine phosphatase/DUSP phosphatase activity prevents nuclear accumulation of phosphorylated ERK1/2 in IECs expressing oncogenic KRAS and BRAF.
Activation of the KRAS/BRAF/MEK/ERK signaling pathway induces DUSP4 expression that correlates with the loss of nuclear ERK phosphorylation As nuclear dephosphorylation of ERK1/2 occurred 2 h after activation of BRAF (Figure 1c ), we postulated that putative nuclear phosphatases were neo-synthesized. We thus analyzed the expression of nuclear DUSPs known to target ERK1/2, namely DUSP1, DUSP4 and DUSP5 (Kondoh and Nishida, 2007; Kucharska et al., 2009) . As shown in Figure 3a , DUSP4 and DUSP5 mRNA levels were rapidly increased following BRAF
:ER activation in an MEK-dependent manner. DUSP1 mRNA levels, however, were not altered following Tamoxifen and U0126 treatments. Although DUSP5 protein expression could not be confirmed by western blot owing to the lack of a specific antibody, we confirmed the induction of DUSP4 protein following BRAF V600E :ER activation ( Figure 3b ). Interestingly, western blot analyses revealed that ERK1/2 were not concomitantly dephosphorylated (Figure 3b ), probably due to persistent BRAF V600E activation of MEK/ERK proteins into the To confirm the correlation between elevated DUSP4 expression and nuclear ERK dephosphorylation, we determined the number of cells positive or not for DUSP4 and phospho-ERK stainings. As summarized in Figure 3d , DUSP4 protein began to be detectable in few cells 30 min after BRAF activation and was expressed in 23.6% of cells after 2 h, a time period corresponding to the reduction of nuclear ERK phosphorylation. After 4 h, more than 60% of phospho-ERK-positive cells expressed DUSP4, but none of them exhibited nuclear phospho-ERK signal. Of note, however, DUSP4 protein was expressed only in cells positive for cytoplasmic ERK-dependent regulation of DUSP4 expression S Cagnol and N Rivard phospho-ERK staining ( Figure 3c , panels 2 and 6, 3 and 4 and 7 and 8 and Figure 3d ). On the other hand, KRAS G12V cells also exhibited marked nuclear DUSP4 expression associated with the absence of nuclear ERK phosphorylation (Figure 3f ). Interestingly, treatment with U0126 totally abolished the induction of DUSP4 expression in both BRAF V600E (Supplementary Figure  S2b) and KRAS G12V cells (Figure 3e ), confirming the direct implication of the MEK/ERK pathway.
Taken together, these data demonstrate that activation of ERK1/2 by serum or oncogenes such as BRAF V600E or KRAS G12V rapidly induces DUSP4 gene and protein expression in IECs.
The oncogenic KRAS/BRAF/MEK/ERK pathway promotes DUSP4 protein stability As serum-induced DUSP4 protein expression disappeared rapidly after ERK pathway extinction (Supplementary Figure S2a ), we therefore speculated that DUSP4 protein was destabilized owing to the loss of ERK activity. To study its half-life, DUSP4 was accumulated after 14 h of Tamoxifen treatment before the addition of protein synthesis inhibitor cycloheximide. As shown in Figure 4a , expression of DUSP4 declined after 30 min of cycloheximide treatment, yielding an estimated DUSP4 protein half-life of 1.5 h. Concomitant inhibition of MEK by U0126 rapidly abolished ERK1/2 phosphorylation and dramatically accelerated DUSP4 protein degradation, giving an estimated half-life of 7.5 min (Figure 4b ). Of note, following ERK1/2 inactivation, DUSP4 protein exhibited an increase in electrophoretic mobility (shift-down, see arrows). Similar results were obtained with CI-1040, another specific inhibitor of MEK (Supplementary Figure S2c) . These results were also illustrated in Figure 4c , which showed that U0126 þ cycloheximide abrogated KRAS G12V -and BRAF V600E -induced phosphorylation of ERK1/2 as well as nuclear DUSP4 expression.
DUSP4 destabilization involves proteasome activity
Previous reports have reported that protein destabilization of DUSP1 (Brondello et al., 1999; Lin and Yang, 2006) , DUSP4 (Peng et al., 2010) , DUSP5 (Kucharska et al., 2009) and DUSP6 (Marchetti et al., 2005) involved proteasome activity. Herein, inhibition of proteasome by either N-Acetyl-Leu-Leu-Norleu-al or MG132 partially rescued the loss of DUSP4 following U0126 þ cycloheximide treatment (Figure 5a ). This partial restoration of DUSP4 levels might be attributable to the fact that the treatment with U0126 also abolished DUSP4 expression at the mRNA level (Figure 4a ). In addition, proteasome inhibition increased basal DUSP4 expression in non-stimulated BRAF
V600E
:ER cells (Supplementary Figure S2d) . Following transient transfection of 293T cells with plasmids encoding for mouse DUSP4 and HA-tagged ubiquitin and treatment with MG132, we were able to detect HA-ubiquitin-conjugated higher molecular weight forms in DUSP4 immunoprecipitates (Figure 5b ), supporting that DUSP4 was ubiquitinated and degraded through proteasome.
DUSP4 stability depends on its phosphorylation
Our results tightly associated DUSP4 stability with change in its electrophoretic mobility and with ERK activity (Figure 4b and Supplementary Figure S2c) . We speculated that ERK1/2 may stabilize DUSP4 by phosphorylation. As ERK1/2 are proline-directed serine/threonine kinases, DUSP4 amino-acid sequence was examined with the prediction software GPS (http:// bioinformatics.lcd-ustc.org/gps_web) for potential SP or TP phosphorylation motifs. We found eight potential sites conserved between human, rat and mouse protein sequences. Four of these sites had a strong probability of being phosphorylated by ERK: a cluster of two threonines on positions 361 and 363 and a cluster of two serines on position 390 and 395 (amino acid position based on the mouse sequence). Thus, we substituted the potential phospho-acceptor residues to alanines by sitedirected mutagenesis. These mutants were transiently expressed in 293T cells and phorbol-12-myristate-13-acetate (PMA) was used to endogenously stimulate ERK1/2 activity. As overexpression of wild-type DUSP4 markedly reduced PMA-induced ERK1/2 activation, we were unable to detect decreased electrophoretic mobility (shift-up) of DUSP4 protein (Figure 6a, lanes 1-3) . However, when a catalytically inactive mutant of DUSP4 was expressed (mutation of the active site cysteine C284 residue to serine), ERK1/2 activation was markedly increased in response to PMA and the DUSP4 C284S protein exhibited a clear electrophoresis shift-up (Figure 6a) . Each of the :ER cells were exponentially grown on glass coverslips, treated with 250 nM Tam for the indicated times and then were analyzed by indirect immunofluorescence for the expression of phosphorylated ERK1/2 (upper panels) and DUSP4 (lower panels). Scale bar: 50 mm. (d) Immunofluorescence experiment depicted in (c) was quantified for % of cells exhibiting phospho-ERK staining (pERK þ ), % of phospho-ERK-positive cells exhibiting nuclear phospho-ERK (nuclear pERK þ ), % of phospho-ERK-positive cells exhibiting DUSP4 staining (total pERK þ DUSP4 þ ), % of phospho-ERK-positive cells exhibiting nuclear phospho-ERK and DUSP4 stainings (nuclear pERK þ DUSP4 þ ) and % of phospho-ERK-negative cells exhibiting DUSP4 staining (pERKÀ DUSP4 þ ). For each condition, 100 cells were counted. (e) Exponentially growing pBabepuro or KRAS G12V cells were treated or not with 20 mM U0126 for 24 h. Equal amounts of protein lysates were analyzed by western blotting for the expression of DUSP4 and total ERK2. (f) KRAS G12V cells were grown on glass coverslips and then analyzed by indirect immunofluorescence for the expression of activated phosphorylated-ERK1/2 and DUSP4. Scale bar: 50 mm.
ERK-dependent regulation of DUSP4 expression S Cagnol and N Rivard double mutations within the two ERK potential phosphorylation sites clusters, namely DUSP4 C284S/ S390A/S395A and DUSP4 C284S/S361A/S363A, exhibited an attenuated PMA-induced electrophoresis mobility shift-up, indicating that these putative serines and threonines were indeed phosphorylated in response to endogenous MEK/ERK1/2 activation ( Figure 6a) . As a complementary experiment, we overexpressed the mutants in 293T cells and performed a kinase assay with recombinant ERK1 after their immunoprecipitation. As shown in Figure :ER cells were treated with 250 nM Tamoxifen (Tam) for 14 h before treatment with 10 mg/ml cycloheximide (CHX) and 20 mM U0126 for 1 h in the presence or not of the proteasome inhibitors MG132 (100 mM) or N-AcetylLeu-Leu-Norleu-al (LLnL) (60 mM). Equal amounts of lysates were analyzed by western blotting for the expression of DUSP4, phosphorylated ERK1/2 and total ERK2. (b) The 293T cells were co-transfected with pSG5 plasmid encoding for mouse wild-type (WT) DUSP4 and pCDNA3 plasmid encoding for HA6-tagged ubiquitin. After 48 h, cells were treated or not with MG132 (50 mM) for 10 h. Cells were lysed and DUSP4 protein was immunoprecipitated. Equal amounts of whole-cell lysates were analyzed by western blotting for the expression of DUSP4. Equal amounts of immunoprecipitates were analyzed for the expression of HA tag. :ER cells were treated with 250 nM Tamoxifen (Tam) for 14 h before the addition of 10 mg/ ml cycloheximide (CHX) with or without 20 mM U0126 for the indicated time periods. Equal amounts of lysates were analyzed by western blotting for the expression of DUSP4, phosphorylated-ERK1/2 and total ERK2. (c) Panels 1-4: BRAF
V600E
:ER cells were grown on glass coverslips and then treated with 250 nM Tam for 14 h (panels 1 and 2). In panels 2 and 4, cells were also treated with 10 mg/ml CHX and 20 mM U0126 for 1 h. Panels 5-8: KRAS G12V cells were grown on glass coverslips. In panels 6 and 8, cells were treated with 10 mg/ml CHX and 20 mM U0126 for 1 h. Cells were analyzed by indirect immunofluorescence for the expression of phosphorylated ERK1/2 (upper panels) and DUSP4 (lower panels). Insets show 4 0 ,6-diamidino-2-phenylindole (DAPI) staining. Scale bars: 50 mm.
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whereas each of the double mutants exhibited an attenuated ERK1-induced electrophoresis mobility shift-up, indicating that these serines and threonines were indeed efficiently and directly phosphorylated by exogenous ERK1.
As ERK activity correlated with DUSP4 stabilization, we analyzed the stability of the phosphorylation mutants in a context of an active phosphatase closer to physiological conditions. As seen in Figure 6c , mutation of each the two clusters into alanine signifi- Immunoprecipitates were incubated in the absence or presence of recombinant active GST-ERK1 and then analyzed by western blotting for expression of DUSP4 and Myc tag. (c) The 293T cells were transfected with pSG5 plasmid encoding for mouse WT DUSP4, DUSP4 T361A/T363A, DUSP4 S390A/S395A, DUSP4 T361A/ T363A S390A/S395A, DUSP4 T361E/T363E and DUSP4 S390E/S395E. After 24 h, cells were treated with 100 nM PMA for 30 min before treatment with 30 mg/ml cycloheximide for the indicated time periods. Cells were lysed and equal amounts of proteins were analyzed by western blotting for the expression of DUSP4 and b-actin. Expression levels of DUSP4 or mutants (relative to b-actin) observed before cycloheximide treatment (0 h) were set at 100% and half-life was estimated.
cantly reduced the stability of DUSP4 protein. Mutations of the four sites (T361A/T363A/S390A/S395A) did not further affect DUSP4 stability. Conversely, mutation of each of the two clusters into phosphomimetic sites, namely T361E/T363E and S390E/S395E, markedly increased the stability of DUSP4, which became much more stable than the wild-type form, confirming the involvement of phosphorylation of these residues in the control of DUSP4 protein stability.
DUSP4 gene expression is upregulated in human CRC cells and correlated with nuclear ERK1/2 inhibition We next evaluated a panel of human CRC cell lines for steady-state localization of phosphorylated ERK1/2. As shown in Figure 7a , ERK phosphorylation was mostly confined to the cytoplasm in all CRC cell lines analyzed (Caco-2/15, DLD1, HT29 and Colo205 are not shown). Treatment of all of these cells with pervanadate restored phosphorylated ERK1/2 in the nucleus, indicating that persistent tyrosine phosphatase/DUSP phosphatase activity inhibits nuclear accumulation of phosphorylated ERK1/2. Accordingly, DUSP4 mRNAs were expressed at high level, in an MEK-dependent manner, in all KRAS and BRAF mutant CRC cells (Figure 7b ). Finally, we transiently overexpressed the catalytically inactive mutant of mouse DUSP4 (DUSP4 C284S) in CRC cells and analyzed the impact on phosphorylated ERK localization. Interestingly, as shown in Figure 7c (arrows), overexpression of DUSP4 C284S in SW480 and LoVo cells restored nuclear phospho-ERK staining, confirming the implication of nuclear DUSP4 in dephosphorylation and tethering of ERKs into the nucleus. Of note, lowest expression of DUSP4 C284S was much less efficient to re-establish a strong nuclear level of phospho-ERK (Figure 7c , arrowheads).
Discussion
Aberrant activation of the KRAS/BRAF/MEK/ERK pathway is frequently associated with colorectal carcinogenesis. Indeed, gain-of-function mutations in KRAS and BRAF genes are observed in up to 50% of colorectal tumors Rajagopalan et al., 2002; Yuen et al., 2002; Nishimura, 2008) . Herein, we analyzed the spatiotemporal regulation of ERK1/2 in IECs expressing the human oncogenic forms of KRAS (KRAS G12V ) and BRAF (BRAF V600E ). As expected, expression of these oncogenes markedly and persistently stimulated ERK1/2 activities. Importantly however, ERK phosphorylation was not observed in the nucleus, but restricted to the cytoplasm of KRAS G12V -and BRAF V600E -transformed IECs. Indeed, although oncogenic BRAF V600E -driven MEK activity rapidly induced nuclear ERK1/2 activity, phosphorylated ERK1/2 disappeared from the nucleus after 2 h and remained absent from the nucleus 5 days after constitutive oncogenic activation of BRAF, and during the transformation process. Accordingly, ERK phosphorylation was found to be confined to the cytoplasm in all human CRC cell lines analyzed. The absence of nuclear phosphorylation of ERK1/2 was not due to their sequestration by cytoplasmic anchors (Formstecher et al., 2001; Smith et al., 2004) , as ERK2 protein was present both in the nucleus and cytoplasm during oncogenic stimulation, nor by an active export to the cytoplasm, as inhibition of nuclear export by leptomycin B did not increase the level of nuclear phosphorylated ERK1/2. As treatment of BRAF V600E -and KRAS
G12V
-expressing IECs with serum did not restore nuclear ERK phosphorylation, we thus speculated that the absence of nuclear ERK phosphorylation was due to their rapid dephosphorylation into the nucleus. In this respect, short-term treatment with pervanadate recovered the nuclear localization of phosphorylated ERK1/2 in both BRAF V600E -and KRAS G12V -transfomed IECs, as well as in human CRC cells, thus validating our hypothesis.
Our observation that nuclear ERK was dephosphorylated within a few hours following their activation is reminiscent of the previously reported regulation of ERK1/2 activity in non-transformed cells in response to serum growth factors (Brondello et al., 1997) , phorbol esters (Caunt et al., 2008a, b) or to the expression of an active truncated form of Raf1 (Volmat et al., 2001) . However, our data demonstrate for the first time that such nuclear inactivation of ERK1/2 also occurs in response to the KRAS G12V and BRAF V600E oncogenes, which are frequently found in CRC cells. Thus, the nuclear dephosphorylation of ERK1/2 rapidly occurring during oncogenic KRAS G12V or BRAF V600E activation precedes the establishment of the morphologically transformed phenotype. Nevertheless, we cannot exclude that during oncogenesis, a very low nuclear ERK activity, not detectable under our experimental conditions, might be sufficient to phosphorylate a very specific set of nuclear substrates. In this regard, the persistent presence of ERK2 protein was detected in the nucleus of KRAS-and BRAF-transformed IECs, suggesting the permanent entry of phosphorylated ERK1/2 into the nucleus during long-term oncogenic stimulation. Moreover, activated BRAF V600E :ER cells consistently exhibited significant increased level of phosphorylated MSK1, a specific nuclear substrate for ERK1/2 (Brami-Cherrier et al., 2005) , as long as tamoxifen was present in the medium (Supplementary Figure S3) . In addition, we observed sustained expression of Fra-1, a transcription factor of the AP-1 family, whose induction and stabilization depend on nuclear ERK activity in various cell types including transformed IECs and CRC cells (Vial and Marshall, 2003; Murphy et al., 2004; Andreolas et al., 2008; Lemieux et al., 2009) .
Nuclear retention of ERK1/2 has been reported to depend on neo-synthesis of nuclear anchors (Lenormand et al., 1998; Caunt et al., 2008b) . Strong evidences suggest that nuclear DUSPs are plausible candidates to anchor ERK1/2 in the nucleus, as DUSPs are induced in response to ERK activation and as mutation of ERK2 within the docking domain (D319N), which inhibits its interaction with D-domain containing protein such as DUSPs (Kondoh and Nishida, 2007; Owens and Keyse, 2007) , decreases nuclear ERK2 retention (Jacobs et al., 1999; Ebisuya et al., 2005; Caunt et al., 2006 Caunt et al., , 2008a Murphy and Blenis, 2006; Armstrong et al., 2009) .
Similarly, in Saccharomyces cerevisiae, the nuclear phosphatase PTP2 and the cytoplasmic phosphatase PTP3 reciprocally regulate both the inactivation and the subcellular localization of the mitogen-activated protein ERK-dependent regulation of DUSP4 expression S Cagnol and N Rivard kinase Hog-1 by tethering Hog-1 (Mattison and Ota, 2000) . Herein, mRNA expression of both DUSP4 and DUSP5 was induced in an MEK-dependent manner in our KRAS-and BRAF-transformed IEC models. Even tough nuclear inactivation of ERK1/2 occurs concomitantly with the rapid nuclear induction of DUSP4 protein, we cannot totally exclude the concomitant contribution of DUSP5. Nevertheless, our results also reveal that ERK1/2 activity controls the stability of DUSP4 protein: indeed, DUSP4 protein levels were maintained as long as ERK1/2 was activated. Such close relationship between DUSP4 protein expression and ERK1/2 phosphorylation underlines the importance of DUSP4 in the control of nuclear ERK activity in IECs.
Previous studies have also reported that phosphorylation of DUSP1 by ERK1/2 promotes either its stabilization (Brondello et al., 1999) or degradation (Lin and Yang, 2006) . Moreover, ERK1/2-mediated phosphorylation of DUSP6 promotes its destabilization (Marchetti et al., 2005) , whereas ERK1/2-mediated phosphorylation of MKP7 promotes its stability (Katagiri et al., 2005) . Our analysis of putative ERK1/2 phosphorylation sequences revealed that T361, T363A, S390 and S395 were all implicated in the stability control of DUSP4. Two of the phosphorylation sites uncovered herein, namely S386 and S391 in humans, were also recently reported to be targeted by ERK. However, in this latter study, the authors did not correlate the phosphorylation of these sites with DUSP4 stability (Peng et al., 2010) . Nevertheless, more studies are needed to clearly elucidate the molecular mechanisms of DUSP4 stability by phosphorylation. DUSP4 dephosphorylation could be a signal required to initiate its degradation into the proteasome. Thus, it could be speculated that phosphorylation of the C-terminal domain of DUSP4 interferes with its binding to a putative ubiquitin ligase.
As DUSP4 expression was markedly induced in IECs transformed by KRAS and BRAF oncogenes as well as in CRC cells in a MEK/ERK-dependent manner, this indicates that DUSP4 functions as part of a negative feedback mechanism in controlling the duration and magnitude of nuclear ERK activation during colorectal oncogenesis in human. Our findings reinforce the notion that ERK activation must be tightly controlled during oncogenesis both temporally and spatially to prevent adverse effects associated with abnormal activation of this pathway. Interestingly, it was recently reported that cytoplasmic ERK activation was correlated with BRAF mutational status in human colorectal tumors (Yeh et al., 2009) . Furthermore, global gene expression microarrays conducted in biopsies from 65 patients with advanced rectal cancer identified DUSP4 as one of the genes that is upregulated in KRAS mutant colorectal tumors (Gaedcke et al., 2010) . Thus, by inducing its own negative and specific regulator, namely DUSP4, ERK thereby ensures that signaling is turned off at the appropriate time in the nucleus. This would suggest that sustained nuclear ERK1/2 activation could be deleterious for cancer cells. As a result, ERK1/2-targeting nuclear phosphatases might represent rational targets for novel therapeutics in CRC exhibiting oncogenic abnormalities in the KRAS/BRAF/ERK signaling pathway. Cell culture pBabepuro and KRAS G12V IEC-6 cells were generated after retroviral infection and were used for o10 passages. Retrovirus preparation and infection were performed as described (Lemieux et al., 2009 ). IEC-6 and 293T cells were cultured in Dulbecco's modified Eagle's medium containing 5% fetal calf serum, 50 U/ml penicillin and 50 mg/ml streptomycin (Wisent, St-Bruno, QC, Canada). BRAF V600E :ER T1 IEC-6 cells were generated and cultured as described (Bergeron et al., 2010) . Human colon adenocarcinoma cell lines were cultured as described (Bergeron et al., 2010) .
Materials and methods
Materials
Antibodies
Antibodies recognizing bi-phosphorylated ERK1/2 were purchased from Sigma-Aldrich. Anti-ERK2 (C14), anti-DUSP4 (S18) (which does not recognize the human protein), anti-DUSP5 (C18 and H74), anti-HA (F7) and anti-Fra-1 (R20) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-MSK1 (Thr 581) was purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-bactin was purchased from Chemicon International (Billerica, MA, USA). Horseradish peroxidase antibodies were purchased from Amersham Biosciences (Pittsburg, PA, USA), whereas alkaline phosphatase-conjugated antibodies were purchased from Promega (Madison, WI, USA). Alexa-564-coupled anti-mouse and Alexa-488-coupled antibodies were purchased from Molecular Probes (Eugene, OR, USA).
Transient transfection
Transient transfection experiments were performed using the calcium phosphate technique in 293T cells (Cagnol et al., 2006) and using Lipofectamine 2000 (Life Technologies, Grand Island, NY, USA) in SW480 and Lovo cells.
Immunoprecipitations and kinase assay Immunoprecipitations were performed as described previously (Simoneau et al., 2011) . For in vitro kinase assay, beads were washed twice in kinase buffer (25 mM Tris (pH 7.5), 10 mM MgCl 2 , 10 mM sodium vanadate, 5 mM b-glycero-phosphate, 2 mM EDTA), followed by a final incubation in the presence or not of recombinant GST-ERK1 kinase (Upstate Biotech, Lake Placid, NY, USA) and incubated for 30 min at 30 1C.
Reactions were terminated by adding 4 Â Laemmli buffer.
